- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Timely Detection: Incidence and Prevalence of Ph+ ALL
Vivian Tambe Ebot-Tar, PharmD, MBA, guides a discussion on the incidence of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and how payers can have the most impact through early treatment coverage.
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Jonathon Abbas, MD; Vivian Tambe Tar, PharmD, MBA; Elias Jabbour, MD; and James McCloskey, MD.
The discussants characterize Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) as a rare leukemia, with an incidence of approximately 6000 cases per year in the United States. Ebot-Tar notes that in a health plan with over 1 million members, the incidence would be approximately 4 to 5 cases per million members. The incidence increases with age. McCloskey emphasizes the importance of timely detection and treatment for optimal outcomes. Targeted therapies are crucial.
Haumschild asks about ensuring timely access to appropriate therapies through payer policies. Ebot-Tar discusses the need to balance cost considerations with ensuring access, using management strategies judiciously to avoid barriers to needed care. Jabbour advocates for optimal upfront therapy to provide the best chance for response and long-term value. The group agrees that durable initial response is ideal to improve overall survival, which drops with later lines of therapy, and that payers should understand the clinical and economic rationale for this approach.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
